Salt-Compact Albumin as a New Pure Protein-based Biomaterials: From Design to In Vivo Studies.

Fiche publication

Date publication

janvier 2025

Journal

Advanced healthcare materials

Auteurs

Membres identifiés du Cancéropôle Est :
Dr FRISCH Benoit , Dr LAVALLE Philippe , Pr SCHAAF Pierre

Tous les auteurs :
Aloui E, Beurton J, Medemblik C, Hugoni L, Clarot I, Boudier A, Arntz Y, De Giorgi M, Combet J, Fleith G, Mathieu E, Kharouf N, Kocgozlu L, Heinrich B, Favier D, Brender M, Boulmedais F, Schaaf P, Frisch B, Lavalle P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39846332

Résumé

Current biodegradable materials are facing many challenges when used for the design of implantable devices because of shortcomings such as toxicity of crosslinking agents and degradation derivatives, limited cell adhesion, and limited immunological compatibility. Here, a class of materials built entirely of stable protein is designed using a simple protocol based on salt-assisted compaction of albumin, breaking with current crosslinking strategies. Salt-assisted compaction is based on the assembly of albumin in the presence of high concentrations of specific salts such as sodium bromide. This process leads, surprisingly, to water-insoluble handable materials with high preservation of their native protein structures and Young's modulus close to that of cartilage (0.86 MPa). Furthermore, these materials are non-cytotoxic, non-inflammatory, and in vivo implantations (using models of mice and rabbits) demonstrate a very slow degradation rate of the material with excellent biocompatibility and absence of systemic inflammation and implant failure. Therefore, these materials constitute promising candidates for the design of biodegradable scaffolds and drug delivery systems as an alternative to conventional synthetic degradable polyester materials.